论文部分内容阅读
目的:观察阿德福韦酯单用与拉米夫定/阿德福韦酯序贯治疗慢性乙型肝炎的疗效。方法:75例慢性乙型肝炎患者分为单用阿德福韦酯组41例,每日服用阿德福韦酯10 mg,疗程48周。拉米夫定/阿德福韦酯序贯治疗组34例,每日服用拉米夫定100 mg,24周后换用阿德福韦酯10 mg,总疗程48周。结果:联合治疗组在12周时有更高的ALT复常率及HBVDNA转阴率(P<0.05)。结论:序贯治疗组具有更高的早期应答率,有助于尽快控制病情。
Objective: To observe the efficacy of adefovir dipivoxil alone and lamivudine / adefovir dipivoxil sequential treatment of chronic hepatitis B. Methods: Seventy-five patients with chronic hepatitis B were divided into adefovir dipivoxil group (n = 41) and adefovir dipivoxil 10 mg daily for 48 weeks. Lamivudine / adefovir dipivoxil sequential treatment group of 34 patients taking daily lamivudine 100 mg, 24 weeks later switched to adefovir dipivoxil 10 mg, the total course of 48 weeks. Results: The combined treatment group had higher rates of ALT recovery and HBVDNA negative conversion (P <0.05) at 12 weeks. Conclusion: Sequential treatment group has a higher early response rate, help to control the disease as soon as possible.